Saghmos Therapeutics to Present at the 25th BioCentury Future Leaders Conference in New York

NEW YORK--(BUSINESS WIRE)-- Saghmos Therapeutics, Inc., a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes, today announced that it will present at the 25^th BioCentury Future Leaders conference New York City.

Anna Kazanchyan, M.D., Chief Executive Officer and Chairwoman of Saghmos, will provide an overview of the company and its lead program, ST-62516, which is positioned to enter Phase 3 development to improve cardiorenal outcomes in patients undergoing percutaneous coronary intervention (PCI). The presentation is scheduled for Friday, March 23, 2018, at 2pm EDT in Room 402/403 at the Millennium Broadway Hotel & Conference Center in New York, NY.

About Saghmos Therapeutics
Saghmos Therapeutics is a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes. Saghmos’ lead program, ST-62516 is positioned to enter Phase 3 development for reduction of major adverse renal and cardiac events (MARCE) associated with contrast-induced acute kidney injury (CI-AKI) in patients undergoing percutaneous coronary intervention (PCI). CI-AKI is a silent killer, leading to heart attacks, prolonged hospitalization, need for dialysis and death. It is a multi-billion dollar market opportunity, with no FDA-approved drugs for prevention or treatment.